International journal of clinical practice
-
Int. J. Clin. Pract. · Jun 2021
Randomized Controlled TrialDeterminants of incorrect inhaler technique in chronic obstructive pulmonary disease patients.
There is a lack of an overview of determinants of incorrect inhaler technique among chronic obstructive pulmonary diseases (COPD) subjects. The aim of this study was to determine the prevalence and possible determinants of incorrect inhaler technique in COPD subjects with common inhalers. ⋯ Incorrect inhaler techniques are highly prevalent among COPD subjects. Lack of past-experience, certain inhaler types, female gender, older age and lower GOLD group are the most significant determinants of incorrect technique.
-
Int. J. Clin. Pract. · Jun 2021
Randomized Controlled TrialThe Potential Hepatoprotective Effect of Metformin in Hepatitis C Virus-infected Adolescent Patients with Beta Thalassemia Major: Randomized Clinical Trial.
Iron overload-induced oxidative stress and transfusion-acquired hepatitis C virus (HCV) infection are the main reasons of liver damage in beta thalassemia major (β-TM). ⋯ The use of metformin in HCV-infected β-TM adolescent patients as an adjuvant antioxidant hepatoprotective agent is promising and can improve liver damage.
-
Int. J. Clin. Pract. · Jun 2021
Randomized Controlled TrialEffects of alpha lipoic acid on iron overload, lipid profile and oxidative stress indices in β-thalassemia major patients: A cross-over randomized controlled clinical trial.
β-Thalassemia major (β-TM) is associated with iron overload, abnormal lipid levels and oxidative stress. Alpha lipoic acid (ALA) showed anti-oxidant and iron chelating properties, but its effect in β-TM patients is unclear. We investigated the effects of ALA on iron levels, lipid profile and oxidative stress. ⋯ The results of this study indicated that supplementation with 600 mg/d ALA may decrease serum ferritin in β-TM. Further studies are needed to confirm the findings.
-
Int. J. Clin. Pract. · Jun 2021
Randomized Controlled TrialDexamethasone Vs. COVID-19: An Experimental Study in Line with the Preliminary Findings of a Large Trial.
The preliminary report of the RECOVERY large randomised controlled trial indicated a promising survival effect for dexamethasone therapy of coronavirus disease 2019 (COVID-19). This study aimed to investigate the anti-hypoxic activities of dexamethasone to understand a possible mechanism of its action in hypoxia-induced lethality through experimental models of hypoxia. ⋯ This experimental in vivo investigation demonstrated an excellent protective effect for 10 days of dexamethasone treatment against hypoxia, especially in asphyctic and hemic models. In addition to promising dexamethasone outcomes, using propranolol as the positive control illustrated a very substantial anti-hypoxic effect even much better than dexamethasone in all models. It seems that propranolol would be a safe, potential, and prudent choice to invest in treating COVID-19 patients.
-
Int. J. Clin. Pract. · Jun 2021
Randomized Controlled TrialComparison of Losartan and Amlodipine Effects on the Outcomes of Patient with COVID-19 and Primary Hypertension: A Randomized Clinical Trial.
Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID-19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID-19. ⋯ There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first-line anti-HTN medications in COVID-19.